bortezomib,daratumumab,dexamethasone
janssen
[]
hematologic cr rate mo. 25% with dara-monotherapy in stage iiib al (half of andromeda). although promising, we need higher cr rate imo to improve long-term outcomes further. #ash22 
Hematologist/Cancer Doctor/Clinical Researcher @ColumbiaCancer 
#Myeloma #Amyloidosis
Asst. Prof @ColumbiaMed
Host @BloodCancerTalk
COI: https://t.co/du0rVN9gca